Metformin activates AMPK and inhibits mTOR — the same pathways engaged by caloric restriction — and observational data suggest diabetic patients on metformin outlive matched non-diabetic controls, but RCT longevity evidence in non-diabetics is pending.
Metformin activates AMPK and inhibits mitochondrial complex I, reducing mTOR signalling and mimicking aspects of caloric restriction at the molecular level. A landmark observational study found that type 2 diabetics on metformin had longer survival than matched non-diabetic controls — a striking finding given that diabetes itself reduces life expectancy. The TAME (Targeting Aging with Metformin) trial is currently testing metformin in non-diabetic older adults; results are expected by 2027.
Bannister et al. (2014) in Diabetes, Obesity and Metabolism compared survival in 78,241 type 2 diabetics on metformin with 12,222 on sulfonylureas and 90,463 matched non-diabetic controls. Metformin-treated diabetics had significantly longer survival than those on sulfonylureas (HR 0.85) and, remarkably, longer survival than the non-diabetic controls (HR 0.85) — suggesting metformin may extend lifespan beyond its glucose-lowering effects. Martin-Montalvo et al. (2013) demonstrated that metformin extended lifespan in mice by 5.83% and improved healthspan. The proposed mechanisms include AMPK activation, mTOR inhibition, reduced oxidative stress, and anti-inflammatory effects.
"Type 2 diabetics treated with metformin had longer survival than matched non-diabetic controls — suggesting metformin may have longevity effects beyond glucose control."
— Bannister et al., Diabetes, Obesity and Metabolism 2014
The NIA is funding the TAME trial — the first RCT to test a drug specifically for its ability to delay aging and age-related disease in non-diabetic older adults. The NIA notes that metformin is one of the most promising candidates for a longevity drug given its safety profile, low cost, and mechanistic plausibility. MedlinePlus identifies metformin as a first-line treatment for type 2 diabetes, noting its safety and effectiveness. Neither the FDA nor any major health authority currently recommends metformin for longevity in non-diabetics outside of clinical trials.
Metformin is not currently approved for longevity use in non-diabetics and should not be self-prescribed for this purpose. For individuals with type 2 diabetes or prediabetes, metformin is a well-established first-line medication with an excellent safety profile. The TAME trial results will provide the first RCT evidence for metformin's longevity effects in non-diabetics. In the meantime, the molecular pathways activated by metformin (AMPK, mTOR inhibition) can be engaged through regular aerobic exercise and avoiding caloric excess.
Vitaei verdict
Metformin has compelling mechanistic and observational evidence for longevity effects, but RCT evidence in non-diabetics is pending. It should not be used for longevity outside of clinical trials.
How Does Caloric Restriction Extend Lifespan and What Is the Human Evidence?
Caloric restriction extends lifespan in virtually every organism studied, from yeast to primates, through activation of AMPK, inhibition of mTOR, and sirtuins — but human evidence remains limited to biomarker improvements rather than direct longevity data.
How to Improve Insulin Sensitivity: An Evidence-Based Guide
Insulin sensitivity is crucial for metabolic health. This article reviews the robust evidence for lifestyle interventions, particularly diet and exercise, in enhancing insulin action and mitigating insulin resistance.